Home > Neurology > MTIS 2020 > Contents > Less medication use and fewer doctor visits with galcanezumab in treatment-resistant migraine

Less medication use and fewer doctor visits with galcanezumab in treatment-resistant migraine

Presented By
Prof. Julio P. Gómez, Hospital Universitario Marqués de Valdecilla, Spain
Conference
MTIS 2020
Trial
Phase 3, CONQUER
  Galcanezumab-treated patients with treatment-resistant migraine had clinically meaningful reductions in days with acute headache medication use. In addition, numerically fewer migraine-specific healthcare-professional visits were observed in patients taking galcanezumab in the CONQUER trial [1]. Treatment-resistant migraine is associated with decreased health-related quality of life and increased economic burden. CONQUER was a 3-month double-blind trial with 462 participants. Participants  had treatment-resistant episodic or chronic migraine, and had failed 2-4 prior migraine preventive classes due to lack of effectiveness or unacceptable safety/tolerability. At baseline, mean use of acute headache medication was 12.3 days per month. Of all patients, 44.8% had acute headache medication overuse. The ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on